Abnormal function of the adaptive immune system drives a diverse set of chronic and acute immune-driven diseases. At Seismic, we are building a pipeline of novel biologics derived from our IMPACT platform focused on addressing the unmet need in dysregulated adaptive immunity to have a broad impact on patients.

We have emerging novel, first-in-class and best-in-class antibody and enzyme programs modulating the two arms of the adaptive immune system, cell-mediated immunity and humoral immunity. For diseases of cell-mediated immunity characterized by inappropriately activated T cells, we are discovering and developing Dual-cell Bidirectional (DcB) antibody therapies that activate multiple inhibitory pathways in more than one cell type to regulate both sides of the immune cell synapse. For diseases of humoral immunity driven by autoantibodies that recognize one’s own tissues, we are discovering and developing multiple types of immunoglobulin sculpting (IgSc) enzyme therapeutics that modify different pathogenic Ig, including immunoglobin G (IgG) proteases. For diseases of humoral dysfunction causing allergic disease and atopy, we are discovering and developing immunoglobin E (IgE) specific proteases.